https://www.selleckchem.com/pr....oducts/tofa-rmi14514
Pemphigus is a debilitating immunoglobulin G (IgG)-mediated autoimmune disease in need of better tolerated, more targeted and rapid onset therapies. ALXN1830 is a humanized IgG4 antibody that blocks neonatal Fc receptor (FcRn) interactions with IgG. A multicenter, open-label safety and tolerability phase 1b/2 trial (NCT03075904) was conducted in North America from July 2017 to January 2019 and included patients aged ≥ 18 years with a confirmed diagnosis of pemphigus (vulgaris or foliaceus) and active disease. Dosing included five
Like
Comment
Share
